GLP-1/glucagon dual-acting agonist (obesity / diabetes)
The dual-acting glucagon/GLP-1 agonist activates both the GLP-1 and glucagon receptors, two key gut hormone receptors and may offer better blood sugar and weight loss control than currently available single agonist treatments. The compound builds partly on the effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans.
The Phase 1 trial is a randomized, double-blind, first-in-human study to evaluate the safety and tolerability of single ascending doses in healthy subjects. The study will be conducted in Germany (EudraCT Number: 2017-000295-29; ClinicalTrials.gov Identifier: NCT03175211). Results are expected in late 2018.
Collaboration with Boehringer Ingelheim
Zealand has two collaborations with Boehringer Ingelheim, where they funds all research, development and commercialization activities. Zealand is eligible to receive royalties and milestone payments as follows:
GLP-1/glucagon dual-acting agonist (2011 agreement)
- EUR 365 million outstanding in milestone payments
- High single-digit to low double-digit percentage royalties on global sales